Investor Presentation First Nine Months of 2022
41
Investor presentation First nine months of 2022
Novo Nordisk has a leadership position within the growing
diabetes market
Novo NordiskⓇ
30%
300
CAGR: -3%
Global diabetes market by treatment class¹
Novo Nordisk remains global diabetes value
market leader
Novo Nordisk market share and share of
growth
DKK
billion
40%
Market CAGR: 4%
400
60%
32%
39%
40%
32%
200
CAGR: 16%
20%
CAGR: -4%
20%
100
10%
31%
24%
CAGR: 19%
0
0%
0%
2017
2018
2019
2020
2021
Aug
Aug
Aug
Aug
2012
2022
2019
2022
GLP-1
Insulin
SGLT-2i
DPP-4i
Novo Nordisk
-Takeda
NN market share
-Sanofi
Merck
Astra Zeneca
-J&J
1 Data is based on company reported sales from Sanofi, Eli Lilly, AstraZeneca, GSK, Novartis, Johnson & Johnson, and Merck. Data does not include generic metformin, sulphonylureas or thiazolidinedione
BI: Boehringer Ingelheim; J&J: Johnson & Johnson; NN: Novo Nordisk
Source: IQVIA MAT, August 2022 value figures Note: IQVIA data can be inflated due to use of list prices in the US
-NN share of growth
-Market growth (right axis)
NN growth (right axis)
Eli Lilly
BI
NovartisView entire presentation